🇦🇹 Austria Country × Condition
prostate cancer Clinical Trials in Austria
Active clinical trials for prostate cancer with research sites in Austria. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 2 // Recruiting: 2 Phases: Phase 4, Phase 2 // Updated: Daily
Total Trials
2
Recruiting Now
2
Country
🇦🇹 Austria
Active Trials in Austria (2)
NCT05803941 Phase 4
Recruiting
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Enrollment
700 pts
Country
🇦🇹 Austria
Novartis Pharmaceuticals
View Trial → NCT06259123 Phase 2
Recruiting
Neoadjuvant PSMA-RLT in Oligometastatic PCa
Enrollment
10 pts
Country
🇦🇹 Austria
Medical University of Vienna
View Trial → Frequently Asked Questions
How many prostate cancer clinical trials are active in Austria?
There are currently 2 active clinical trials for prostate cancer with sites in Austria, of which 2 are actively recruiting patients.
How can I join a prostate cancer clinical trial in Austria?
To join a prostate cancer clinical trial in Austria, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Austria directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are prostate cancer trials in Austria?
Active prostate cancer trials in Austria span Phase 4, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology